Trial Profile
A Phase 3, Randomized, Controlled Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma That Has Progressed After Prior VEGFR Tyrosine Kinase Inhibitor Therapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 25 Jul 2022
Price :
$35
*
At a glance
- Drugs Cabozantinib (Primary) ; Everolimus
- Indications Renal cell carcinoma
- Focus Registrational; Therapeutic Use
- Acronyms METEOR
- Sponsors Exelixis
- 01 Jan 2022 Results of post hoc sub-analysis of METEOR study, assessing outcomes for patients recruited from European and non-European countries, published in the Acta Oncologica
- 21 Sep 2020 Trial design presented at the 45th European Society for Medical Oncology Congress
- 31 May 2020 Results of post-hoc pooled analysis of patients who had received prior IO therapy from METEOR and C2001 presented at the 56th Annual Meeting of the American Society of Clinical Oncology